for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSPC Pharmaceutical Group Ltd

1093.HK

Latest Trade

15.38HKD

Change

-0.08(-0.52%)

Volume

30,208,090

Today's Range

15.34

 - 

15.92

52 Week Range

9.90

 - 

19.26

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
15.46
Open
15.50
Volume
30,208,090
3M AVG Volume
800.47
Today's High
15.92
Today's Low
15.34
52 Week High
19.26
52 Week Low
9.90
Shares Out (MIL)
6,236.34
Market Cap (MIL)
96,413.79
Forward P/E
21.95
Dividend (Yield %)
1.16

Next Event

CSPC Pharmaceutical Group Ltd at Macquarie China Healthcare Corporate Day

Latest Developments

更多

CSPC Pharmaceutical Group Says Cefuroxime Axetil Tablets Granted Approval

Cspc Pharmaceutical Says Recombinant Anti-Her2 & Anti-Cd3 Granted Clinical Trial Approval By U.S. FDA

CSPC Pharmaceutical Group Says Anti-Tumor Drug Granted Clinical Trial Approval

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

No. 226 Huanghe Avenue

+86.311.87037015

http://www.cspc.com.hk/

Executive Leadership

Dongchen Cai

Executive Chairman of the Board, Chief Executive Officer

Cuilong Zhang

Executive Vice Chairman of the Board, Rotating Chief Executive Officer

Kin Man Chak

Executive Director

Chunlei Li

Executive Director

Hua Lu

Executive Director

Key Stats

1.71 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2016

12.4K

2017

15.5K

2018

21.0K

2019(E)

25.3K
EPS (HKD)

2016

0.350

2017

0.455

2018

0.586

2019(E)

0.695
Price To Earnings (TTM)
25.25
Price To Sales (TTM)
4.33
Price To Book (MRQ)
5.30
Price To Cash Flow (TTM)
21.20
Total Debt To Equity (MRQ)
1.59
LT Debt To Equity (MRQ)
0.77
Return on Investment (TTM)
22.13
Return on Equity (TTM)
14.97

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up